Last reviewed · How we verify

Cannabis Sativa extract Oromucosal spray

Ospedale San Raffaele · Phase 2 active Small molecule

Cannabis Sativa extract Oromucosal spray is a Small molecule drug developed by Ospedale San Raffaele. It is currently in Phase 2 development. Also known as: Sativex.

At a glance

Generic nameCannabis Sativa extract Oromucosal spray
Also known asSativex
SponsorOspedale San Raffaele
ModalitySmall molecule
PhasePhase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Cannabis Sativa extract Oromucosal spray

What is Cannabis Sativa extract Oromucosal spray?

Cannabis Sativa extract Oromucosal spray is a Small molecule drug developed by Ospedale San Raffaele.

Who makes Cannabis Sativa extract Oromucosal spray?

Cannabis Sativa extract Oromucosal spray is developed by Ospedale San Raffaele (see full Ospedale San Raffaele pipeline at /company/ospedale-san-raffaele).

Is Cannabis Sativa extract Oromucosal spray also known as anything else?

Cannabis Sativa extract Oromucosal spray is also known as Sativex.

What development phase is Cannabis Sativa extract Oromucosal spray in?

Cannabis Sativa extract Oromucosal spray is in Phase 2.

Related